All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the European Hematology Association (EHA) 2023 Hybrid Congress, the AML Hub was pleased to speak with Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, “How might treatment with venetoclax plus hypomethylating agents (HMAs) improve quality of life and post-transplant outcomes?”
How might treatment with venetoclax plus HMAs improve quality of life and post-transplant outcomes?
DiNardo begins by describing patient-reported outcomes and quality-of-life data from the VIALE-A study presented at EHA 2023, including EORTC QLQ-C3, PROMIS-fatigue, and EQ-5D-5L measures. She also discusses the clinical response and survival rates of patients who received venetoclax and HMA treatment prior to transplant, including the relevance of patient age and performance status.
What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
During the 64th ASH Annual Meeting and Exposition, the AML Hub was pleased to speak to Courtney DiNardo, MD Anderson Cancer Center, Houston, US....
Venetoclax in combination with a HMA has been approved by the European Commission for patients with newly diagnosed AML
On May 25, 2021, the European Commission approved venetoclax with a hypomethylating agent for adult patients with newly diagnosed...
Subscribe to get the best content related to AML delivered to your inbox